Abstract
Background:
Animal models based on N-methyl-d-aspartate receptor blockade have been extensively used for schizophrenia. Ketamine and MK-801 produce behaviors related to schizophrenia and exacerbated symptoms in patients with schizophrenia, which led to the use of PCP (phencyclidine)- and MK-801 (dizocilpine)-treated animals as models for schizophrenia.
Methods:
The study investigated the effect of subchronic dosing (once daily, 7 days) of histamine H3 receptor (H3R) antagonists, ciproxifan (CPX) (3 mg/kg, i.p.), and clobenpropit (CBP) (15 mg/kg, i.p.) on MK-801 (0.2 mg/kg, i.p.)-induced locomotor activity and also measured dopamine and histamine levels in rat’s brain homogenates. The study also included clozapine (CLZ) (3.0 mg/kg, i.p.) and chlorpromazine (CPZ) (3.0 mg/kg, i.p.), the atypical and typical antipsychotic, respectively.
Results:
Atypical and typical antipsychotic was used to serve as clinically relevant reference agents to compare the effects of the H3R antagonists. MK-801 significantly increased horizontal locomotor activity, which was reduced with CPX and CBP. MK-801-induced locomotor hyperactivity attenuated by CPX and CBP was comparable to CLZ and CPZ. MK-801 raised striatal dopamine level, which was reduced in rats pretreated with CPX and CBP. CPZ also significantly lowered striatal dopamine levels, although the decrease was less robust compared to CLZ, CPX, and CBP. MK-801 increased histamine content although to a lesser degree. Subchronic treatment with CPX and CBP exhibited further increased histamine levels in the hypothalamus compared to MK-801 treatment alone. Histamine H3 receptor agonist, R-α methylhistamine (10 mg/kg, i.p.), counteracted the effect of CPX and CBP.
Conclusions:
The present study shows the positive effects of CPX and CBP on MK-801-induced schizophrenia-like behaviors in rodents.
Acknowledgments:
The authors acknowledge and thank the Department of Science and Technology, New Delhi, India, for providing financial support for the chemicals and instruments.
Author contributions: Dr. Danish Mahmood designed the research protocol for the study and carried out all the preclinical studies. Dr. Kausar Jahan helped in writing the manuscript and collecting of literatures. Dr. Dipanjan Goswami conducted the LC-MS/MS for estimation of neurotransmitter. Dr. Mohd Akhtar acted as the main supervisor of the study and designed the protocol and guided the entire research work. All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.
Research funding: Department of Science and Technology, Government of India, and DST Fellowship.
Employment or leadership: None declared.
Honorarium: None declared.
Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.
References
1. Jentsch JD, Roth RH. The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 1999;20:201–25.10.1016/S0893-133X(98)00060-8Search in Google Scholar
2. Luby ED, Cohen BD, Rosenbaum G, Gottlieb JS, Kelley R. Study of a new schizophrenomimetic drug; sernyl. AMA Arch Neuro Psychiatry 1959;81:363–9.10.1001/archneurpsyc.1959.02340150095011Search in Google Scholar
3. Javitt DC, Zukin SR. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 1991;148:1301–8.10.1176/ajp.148.10.1301Search in Google Scholar
4. Bubenikova Valesova V, Horácek J, Vrajová M, Höschl C. Models of schizophrenia in humans and animals based on inhibition of NMDA receptors. Neurosci Biobehav Rev 2008;32:1014–23.10.1016/j.neubiorev.2008.03.012Search in Google Scholar
5. Mohn AR, Gainetdinov RR, Caron MG, Koller BH. Mice with reduced NMDA receptor expression display behaviors related to schizophrenia. Cell 1999;98:427–36.10.1016/S0092-8674(00)81972-8Search in Google Scholar
6. Tricklebank MD, Singh L, Oles RJ, Preston C, Iversen SD. The behavioural effects of MK-801: a comparison with antagonists acting non-competitively and competitively at the NMDA receptor. Eur J Pharmacol 1989;167:127–35.10.1016/0014-2999(89)90754-1Search in Google Scholar
7. Manahan-Vaughan D, von Haebler D, Winter C, Juckel G, Heinemann U. A single application of MK801 causes symptoms of acute psychosis, deficits in spatial memory, and impairment of synaptic plasticity in rats. Hippocampus 2008;18:125–34.10.1002/hipo.20367Search in Google Scholar PubMed
8. Yu J, Qi D, Xing M, Li R, Jiang K, Peng Y, et al. MK-801 induces schizophrenic behaviors through downregulating Wnt signaling pathways in male mice. Brain Res 2011;1385:281–92.10.1016/j.brainres.2011.02.039Search in Google Scholar PubMed
9. Gilmour G, Dix S, Fellini L, Gastambide F, Plath N, Steckler T, et al. NMDA receptors, cognition and schizophrenia--testing the validity of the NMDA receptor hypofunction hypothesis. Neuropharmacology 2012;62:1401–12.10.1016/j.neuropharm.2011.03.015Search in Google Scholar PubMed
10. Adell A, Jiménez-Sánchez L, López-Gil X, Romón T. Is the acute NMDA receptor hypofunction a valid model of schizophrenia? Schizophr Bull 2012;38:9–14.10.1093/schbul/sbr133Search in Google Scholar PubMed PubMed Central
11. Arrang JM, Garbarg M, Schwartz JC. Auto-inhibition of histamine release mediated by a novel class (H3) of histamine receptor. Nature 1983;302:832–7.10.1038/302832a0Search in Google Scholar
12. Schlicker E, Malinowska B, Kathmann M, Gothert M. Modulation of neurotransmitter release via histamine H heteroreceptors. Fundam Clin Pharmacol 1994;8:128–37.10.1111/j.1472-8206.1994.tb00789.xSearch in Google Scholar
13. Arrang JM. Histamine and schizophrenia. Int Rev Neurobiol 2007;78:247–87.10.1016/S0074-7742(06)78009-6Search in Google Scholar
14. Ligneau X, Lin J, Vanni-Mercier G, Jouvet M, Muir JL, Ganellin CR, et al. Neurochemical and behavioral effects of ciproxifan, a potent histamine H3-receptor antagonist. J Pharmacol Exp Ther 1998;287:658–66.Search in Google Scholar
15. Pillot C, Ortiz J, Héron A, Ridray S, Schwartz JC, Arrang JM. Ciproxifan, a histamine H3 receptor antagonist/inverse agonist, potentiates neurochemical and behavioral effects of haloperidol in the rat. J Neurosci 2002;22:7272–80.10.1523/JNEUROSCI.22-16-07272.2002Search in Google Scholar
16. Mahmood D, Khanam R, Pillai KK, Akhtar M. Protective effects of Histamine H3 receptor ligands in schizophrenic behaviors in experimental models. Pharmacol Rep 2012;4:191–204.10.1016/S1734-1140(12)70746-6Search in Google Scholar
17. Burban A, Sadakhom C, Dumoulin D, Rose C, Le Pen G, Frances H, et al. Modulation of prepulse inhibition and stereotypies in rodents: no evidence for antipsychotic-like properties of histamine H3-receptor inverse agonists. Psychopharmacology (Berl) 2010;210:591–604.10.1007/s00213-010-1863-2Search in Google Scholar
18. Bardgett ME, Points M, Kleier J, Blankenship M, Griffith MS. The H3 antagonist, ciproxifan, alleviates the memory impairment but enhances the motor effects of MK-801 (dizocilpine) in rats. Neuropharmacology 2010;59:492–502.10.1016/j.neuropharm.2010.07.004Search in Google Scholar
19. Bardgett ME, Davis NN, Schultheis PJ, Griffith MS. Ciproxifan, an H3 receptor antagonist, alleviates hyperactivity and cognitive deficits in the APP Tg2576 mouse model of Alzheimer’s disease. Neurobiol Learn Mem 2011;95:64–72.10.1016/j.nlm.2010.10.008Search in Google Scholar
20. Liljequist S, Ossowska K, Grabowska-Andén M, Andén NE. Effect of the NMDA receptor antagonist, MK-801, on locomotor activity and on the metabolism of dopamine in various brain areas of mice. Eur J Pharmacol 1991;195:55–61.10.1016/0014-2999(91)90381-YSearch in Google Scholar
21. Su F, Wang F, Zhu R, Li H. Determination of 5-Hydroxytryptamine, norepinephrine, dopamine and their metabolites in rat brain tissue by LC–ESI–MS–MS. Chromatographia 2009;69:207–13.10.1365/s10337-008-0879-9Search in Google Scholar
22. Leurs R, Blandina P, Tedford C, Timmerman H. Therapeutic potential of histamine H3 receptor agonists and antagonists. Trends Pharmacol Sci 1998;19:177–83.10.1016/S0165-6147(98)01201-2Search in Google Scholar
23. Akhtar M, Uma DP, Ali A, Pillai KK, Vohora D. Antipsychotic like profile of thioperamide, a selective H3-receptor antagonist in mice. Fundam Clin Pharmacol 2006;20:373–8.10.1111/j.1472-8206.2006.00411.xSearch in Google Scholar PubMed
24. Ligneau X, Landais L, Perrin D, Piriou J, Uguen M, Denis E, et al. Brain histamine and schizophrenia: Potential therapeutic application of H3-receptor inverse agonists studied with BF2.649. Biochem Pharmacol 2007;47:1215–24.10.1016/j.bcp.2007.01.023Search in Google Scholar PubMed
25. Sander K, Kottke T, Stark H. Histamine H3 receptor antagonists go to clinics. Biol Pharm Bull 2008;31:2163–81.10.1248/bpb.31.2163Search in Google Scholar PubMed
26. Gemkow MJ, Devenport AJ, Harich S, Ellenbroek BA, Cesura A, Hallett D. The histamine H3 receptor as a therapeutic drug target for CNS disorders. Drug Discov Today 2009;14:509–15.10.1016/j.drudis.2009.02.011Search in Google Scholar PubMed
27. Raddatz R, Hudkins RL, Mathiasen JR, Gruner JA, Flood DG, Aimone LD. CEP-26401 (irdabisant), a potent and selective histamine H3 receptor antagonist/inverse agonist with cognition-enhancing and wake-promoting activities. J Pharmacol Exp Ther 2012;340:124–33.10.1124/jpet.111.186585Search in Google Scholar PubMed
28. Egan M, Zhao X, Gottwald R, Harper-Mozley L, Zhang Y, Snavely D, et al. Randomized crossover study of the histamine H3 inverse agonist MK-0249 for the treatment of cognitive impairment in patients with schizophrenia. Schizophr Res 2013;146:224–30.10.1016/j.schres.2013.02.030Search in Google Scholar PubMed
29. Haig GM, Bain E, Robieson W, Othman AA, Baker J, Lenz RA. A randomized trial of the efficacy and safety of the H3 antagonist ABT-288 in cognitive impairment associated with schizophrenia. Schizophr Bull 2014;40:1433–42.10.1093/schbul/sbt240Search in Google Scholar PubMed PubMed Central
30. Bardgett ME, Points M, Roflow J, Blankenship M, Griffith MS. Effects of the H(3) antagonist, thioperamide, on behavioral alterations induced by systemic MK-801administration in rats. Psychopharmacology (Berl) 2009;205:589–97.10.1007/s00213-009-1566-8Search in Google Scholar PubMed PubMed Central
31. Schwartz JC. The histamine H3 receptor: from discovery to clinical trials with pitolisant. Br J Pharmacol 2011;163:713–21.10.1111/j.1476-5381.2011.01286.xSearch in Google Scholar PubMed PubMed Central
32. Brown JW, Whitehead CA, Basso AM, Rueter LE, Zhang M. Preclinical evaluation of non-imidazole histamine H3 receptor antagonists in comparison to atypical antipsychotics for the treatment of cognitive deficits associated with schizophrenia. Int J Neuropsychopharmacol 2013;16:889–904.10.1017/S1461145712000739Search in Google Scholar PubMed
33. Howes O, McCutcheon R, Stone J. Glutamate and dopamine in schizophrenia: an update for the 21st century. J Psychopharmacol 2015;29:97–115.10.1177/0269881114563634Search in Google Scholar
34. Hoffman DC. Typical and atypical neuroleptics antagonize MK-801-induced locomotion and stereotypy in rats. J Neural Transm Gen Sect 1992;89:1–10.10.1007/BF01245347Search in Google Scholar
35. Salgado JV, Sandner G. A critical overview of animal models of psychiatric disorders: challenges and perspectives. Rev Bras Psiquiatr 2013;35:S77–81.10.1590/1516-4446-2013-1156Search in Google Scholar
36. Doherty JD, Simonovic M, So R, Meltzer HY. The effect of phencyclidine on dopamine synthesis and metabolism in rat striatum. Eur J Pharmacol 1980;65:139–49.10.1016/0014-2999(80)90386-6Search in Google Scholar
37. Irifune M, Shimizu T, Nomoto M, Fukuda T. Involvement of N-methyl-D-aspartate (NMDA) receptors in noncompetitive NMDA receptor antagonist-induced hyperlocomotion in mice. Pharmacol Biochem Behav 1995;51:291–6.10.1016/0091-3057(94)00379-WSearch in Google Scholar
38. Miller DW, Abercrombie ED. Effects of MK-801 on spontaneous and amphetamine-stimulated dopamine release in striatum measured with in vivo microdialysis in awake rats. Brain Res Bull 1996;40:57–62.10.1016/0361-9230(95)02144-2Search in Google Scholar
39. Mathé JM, Nomikos GG, Hildebrand BE, Hertel P, Svensson TH. Prazosin inhibits MK-801-induced hyperlocomotion and dopamine release in the nucleus accumbens. Eur J Pharmacol 1996;309:1–11.10.1016/0014-2999(96)00315-9Search in Google Scholar
40. Sepúlveda MG, Rosel S, Hoffmann HM, Castillo-Ruiz M, Mignon V, Delgado DM, et al. Cellular distribution of the histamine H3 receptor in the basal ganglia: functional modulation of dopamine and glutamate neurotransmission. Basal Ganglia 2013;3:109–21.10.1016/j.baga.2012.12.001Search in Google Scholar
41. Moghaddam B, Adams B, Verma A, Daly D. Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci 1997;17:2921–7.10.1523/JNEUROSCI.17-08-02921.1997Search in Google Scholar
42. Martin P, Carlsson ML, Hjorth S. Systemic PCP treatment elevates brain extracellular 5-HT: a microdialysis study in awake rats. Neuroreport 1998;9:2985–8.10.1097/00001756-199809140-00012Search in Google Scholar PubMed
43. Ryu JH, Yanai K, Iwata R, Ido T, Watanabe T. Heterogeneous distributions of histamine H3, dopamine D1 and D2 receptors in rat brain. Neuroreport 1998;5:621–4.10.1097/00001756-199401000-00022Search in Google Scholar PubMed
44. Arias-Montano JA, Floran B, Garcia M, Aceves J, Young JM. Histamine H3 receptor-mediated inhibition of depolarization-induced, dopamine D1 receptor-dependent release of [3H]-γ-aminobutyric acid from rat striatal slices. Br J Pharmacol 2001;133:165–71.10.1038/sj.bjp.0704053Search in Google Scholar PubMed PubMed Central
45. Ferrada C, Ferré S, Casadó V, Cortés A, Justinova Z, Barnes C, et al. Interactions between histamine H3 and dopamine D2 receptors and the implications for striatal function. Neuropharmacology 2008;55:190–7.10.1016/j.neuropharm.2008.05.008Search in Google Scholar PubMed PubMed Central
46. Faucard R, Armand V, Héron A, Cochois V, Schwartz JC, Arrang JM. N-methyl-D aspartate receptor antagonists enhance histamine neuron activity in rodent brain. J Neurochem 2006;98:1487–96.10.1111/j.1471-4159.2006.04002.xSearch in Google Scholar PubMed
47. Barr MS, Farzan F, Tran LC, Chen R, Fitzgerald PB, Daskalakis ZJ. Evidence for excessive frontal evoked gamma oscillatory activity in schizophrenia during working memory. Schizophr Res 2010;121:146–52.10.1016/j.schres.2010.05.023Search in Google Scholar PubMed
48. Molina LA, Skelin I, Gruber AJ. Acute NMDA receptor antagonism disrupts synchronization of action potential firing in rat prefrontal cortex. PLoS One 2014;9:e85842.10.1371/journal.pone.0085842Search in Google Scholar PubMed PubMed Central
49. Munari L, Provensi G, Passani MB, Blandina P. Selective brain region activation by histamine H3 receptor antagonist/inverse agonist ABT-239 enhances acetylcholine and histamine release and increases c-Fos expression. Neuropharmacology 2013;70:131–40.10.1016/j.neuropharm.2013.01.021Search in Google Scholar PubMed
50. Morisset S, Traiffort E, Arrang JM, Schwartz JC. Changes in histamine H3 receptor responsiveness in mouse brain. J Neurochem 2000;74:339–46.10.1046/j.1471-4159.2000.0740339.xSearch in Google Scholar PubMed
51. Morisset S, Sahm UG, Traiffort E, Tardivel-Lacombe J, Arrang JM, Schwartz JC. Atypical neuroleptics enhance histamine turnover in brain via 5-Hydroxytryptamine2A receptor blockade. J Pharmacol Exp Ther 1999;288:590–6.Search in Google Scholar
52. Tiedtke PI, Bischoff C, Schmidt WJ. MK-801-induced stereotypy and its antagonism by neuroleptic drugs. J Neural Transm 1990;81:173–82.10.1007/BF01245040Search in Google Scholar PubMed
53. Rodrigues AA, Jansen FP, Leurs R, Timmerman H, Prell GD. Interaction of clozapine with the histamine H3 receptor in rat brain. Br J Pharmacol 1995;114:1523–4.10.1111/j.1476-5381.1995.tb14934.xSearch in Google Scholar PubMed PubMed Central
©2016 Walter de Gruyter GmbH, Berlin/Boston
